###### Strengths and limitations of this study

-   Readability of medicine information sheets (MIS) from three countries (Australia, UK and Canada) was assessed.

-   While readability formulae only measure the number/complexity of words/sentences, Australian patient literal comprehension of MIS was also assessed.

-   The study population was from a regional community and may not be representative of a more urban population.

Introduction {#s1}
============

Health literacy is defined as the 'capacity to obtain, process and understand written and oral health information and services needed to make appropriate health decisions'.[@R1] Low health literacy has been associated with poorer health-related knowledge, increased hospitalisations, reduced immunisations, poorer health status and higher mortality.[@R2] Patients with poor health literacy are less likely to successfully manage chronic disease[@R3] and have greater difficulty in following instructions for prescription medications.[@R4] Higher health literacy has been associated with increased medication adherence.[@R5]

Although the importance of health literacy and patient--physician communication on health outcomes is well recognised, many patients have difficulty in understanding what their physicians tell them.[@R7] Immediately after leaving a consultation with their specialist, patients were able to recall less than half the information just provided to them.[@R8] The provision of written health information in addition to verbal information significantly increases patient knowledge and satisfaction.[@R10] Written information may also lead to increased adherence with treatment.[@R9] However, designing effective written health information remains challenging due to differences in patient literacy levels.

The recommended level of reading difficulty for health-related written material in inconsistent. Some agencies have recommended up to eighth grade level[@R11]---the average reading level of an adult in the USA,[@R12] whereas others have suggested levels as low as fifth grade to be more inclusive of those with limited literacy.[@R14] No national guidelines exist in Australia, although the South Australian government has recommended up to eighth grade level.[@R15] Despite these inconsistencies, many studies have found written health information provided to patients often exceeds these levels.[@R16] While there is greater access to health-related information on the internet, this often also exceeds recommended readability levels.[@R20]

Literacy levels in Australia are poor, with up to 60% of the population having low literacy skills[@R22]---defined as the 'minimum required for individuals to meet the complex demands of everyday life'.[@R24] The International Adult Literacy Survey found 57% of Canadians fall into the lowest two literacy categories.[@R25] In the UK, just under one in six adults has the literacy of an 11-year-old.[@R26] A study of over 200 rural and urban Australian rheumatology patients found that 15% of patients had low health literacy and up to one-third of patients incorrectly followed dosing instructions for common rheumatology drugs.[@R23] Ten per cent of patients with rheumatoid arthritis (RA) who attended an urban community-based Australian rheumatology practice had inadequate/marginal functional health literacy or a reading age at or below the US high school grade equivalent of seventh--eighth grade.[@R27] Up to 24% of rheumatology patients at a US medical centre had a reading level of eighth grade or less.[@R28] In 2002, one in six rheumatology patients at a Scottish hospital were illiterate and struggled to understand education materials and prescription labels.[@R29] These findings are concerning, as rheumatologists often use medications such as methotrexate (MTX) or expensive biological therapies with severe side effects, even death,[@R30] if taken incorrectly.

Given the importance of health literacy and its relationship to health outcomes and medication adherence, we sought to assess: (i) the readability of patient medication information sheets (MIS) given to patients by Australian rheumatologists and (ii) patient comprehension of these documents.

We also compared the readability of the Australian MIS to similar documents given to rheumatology patients in the UK and Canada.

Methods {#s2}
=======

Assessment of readability {#s2a}
-------------------------

Text from the MIS of commonly prescribed rheumatology medications available on the Australian Rheumatology Association (ARA) website[@R31] was imported into a Microsoft Word document and readability assessed using Readability Studio (Oleander Software).[@R18]

Non-essential text including logos, headers, footers, hyperlinks and contact information was deleted prior to analysis as these may have adversely affected readability scores. Readability was assessed using a range of measures such as the Flesch Reading Ease formula, Simple Measure of Gobbledygook (SMOG) scale, FORCAST (named after the authors FORd, CAylor, STicht) and the Gunning Fog scale. The Flesch Reading Ease formula calculates an index score of a document based on sentence length and number of syllables. It is often used for school textbooks and technical manuals. The standard score is between 0 and 100, with a high score indicating the document is easier to read[@R36] (however, it is possible to also gain minus scores and scores over 100). The SMOG formula calculates grade level and reader age based on complex word density and assigns a grade level (fourth grade to college level).[@R33] It is particularly useful for secondary age readers and attempts to predict 100% comprehension, whereas most other formulae predict 50%--75% comprehension. Consequently, SMOG may produce grade level scores one to two grades higher than other formulae.[@R33] The Gunning Fog formula calculates grade level and reader age based on number of sentences, their mean length and number of complex words (three or more syllables).[@R38] The FORCAST readability formula was initially used for assessing technical documents by calculating the grade level of text based on number of monosyllabic words. It is the only test not designed for running narrative, for example multiple choice quizzes and applications. As sentence length is not considered, there may be some variability in grade level compared with other readability formulae.[@R33]

It was felt the above four formulae allowed comprehensive assessment of an MIS by focussing on various aspects: Flesch Reading Ease---sentence length and syllable number, SMOG---complex word density, Gunning Fog---sentence number/length and complex words and FORCAST---number of monosyllabic words and non-dependence on running narrative.

The readability of 10 corresponding MIS of a sample of commonly prescribed rheumatology medications published in the UK by Arthritis Research UK[@R39] and from Canada published by Rheuminfo[@R40] was also assessed as above. These 10 MIS were representative of the MIS available on both these websites.

Assessment of literal comprehension {#s2b}
-----------------------------------

Coffs Harbour is a growing regional city of 70 000 people located half-way between the Australian capital cities of Sydney and Brisbane. Its medical specialists provide services to another 50 000 people from the surrounding area. Rheumatology services are provided by two rheumatologists (PKKW and HB) under the auspices of the Mid-North Coast Arthritis Clinic (MNCAC). The MNCAC has over 16 000 patients on its computerised database.

A random sample of patients referred to the MNCAC was asked to read one ARA MIS[@R31] containing information about one of the following medications which the patient was unfamiliar with: online [supplementary material 1](#SP1){ref-type="supplementary-material"} MTX,[@R41] online [supplementary material 2](#SP2){ref-type="supplementary-material"} non-steroidal anti-inflammatory drugs (NSAIDs),[@R42] online [supplementary material 3](#SP3){ref-type="supplementary-material"} adalimumab (ADA),[@R43] online [supplementary material 4](#SP4){ref-type="supplementary-material"} abatacept (ABA)[@R44] or online [supplementary material 5](#SP5){ref-type="supplementary-material"} prednisone.[@R45] All consecutive patients scheduled for a randomly selected consulting day were contacted via telephone by an investigator (MO or ET). Patients (n=261) were asked whether they were interested in study participation to determine what they understood after reading information from the doctor. Responses are outlined in [figure 1](#F1){ref-type="fig"}. Those who expressed interest in study participation were mailed information about the study and a consent form to be returned in a stamped preaddressed envelope (n=142). Those who agreed to participate were assessed on the day of the planned consultation (n=95). These was no difference in gender or age between those included compared with those not contactable (data not shown). Comprehension was assessed by asking the patient to answer five multiple choice questions (see online [supplementary material 6](#SP6){ref-type="supplementary-material"}) about the content of the one ARA MIS they had just read. These questions were designed by two rheumatologists (PKKW, HB), a rheumatology nurse (DF) and an education academic with expertise in literacy (JJ). The questions were trialled on small focus groups of patients. A time limit of 15 min in a quiet well-lit room was provided. If needed, study participants could refer back to the MIS while answering the questions.
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![Inclusions and exclusions.](bmjopen-2018-024582f01){#F1}

Patient and public involvement {#s2c}
------------------------------

Previous work by us found that up to 15% of patients had low health literacy and up to one-third of patients incorrectly followed dosing instructions for common rheumatology drugs.[@R23] These findings prompted us to conduct this study which examined the readability of MIS routinely used in our clinical practice. Furthermore, some of our patients had previously commented that the ARA MIS were difficult to understand. A summary of study results will be disseminated to all study participants. Patients were not involved in the recruitment to and conduct of the study. However, many study participants indicated they hoped their study involvement would lead to the development of better written material for future patients.

Statistical analyses {#s2d}
--------------------

Descriptive summary statistics (mean ±SD and median ±IQR range, as appropriate) were used to analyse parameters. Student's t-test (unpaired) was used to compare means of normally distributed parameters. The Mann-Whitney U test was used to compare medians of groups. For all statistical tests, p\<0.05 was considered significant. Data analysis was undertaken using GraphPad Prism V.6 (GraphPad Software).[@R46] The correlation (r value) between comprehension score and various parameters (age, gender, postcode, highest level of education) was performed using STATA (Stata V.11.1, StataCorp).

Results {#s3}
=======

Assessment of readability {#s3a}
-------------------------

The mean (±SD) grade level for the ARA MIS calculated using Readability Studio was 11.6±0.1 with a mean reading age of 16.6±0.1 years ([table 1](#T1){ref-type="table"}). (These were obtained by calculating the mean of the FORCAST, Gunning Fog and SMOG mean grade level and reading age. Due to the heterogeneity of these instruments, the mean of each of these measures is available in the relevant table). The mean (±SD) Flesch Reading Ease score of 50.8±0.6 indicated the ARA MIS were either 'fairly difficult' or 'difficult'[@R33] ([table 1](#T1){ref-type="table"}). Overall, difficult sentences (\>22 words) and complex words (≥3 syllables) made up 9.0% and 18.4% of the text, respectively ([table 2](#T2){ref-type="table"}).

###### 

Readability scores for Australian Rheumatology Association Medicine Information Sheets

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                    Flesch Reading Ease [\*](#tblfn1){ref-type="fn"}\   FORCAST grade level   FORCAST reader age (years)   Gunning Fog grade level   Gunning Fog reader age (years)   SMOG grade level   SMOG reader age (years)   Mean grade level†   Mean reader age†\
                                (0--100)                                                                                                                                                                                                                           (years)
  ----------------------------- --------------------------------------------------- --------------------- ---------------------------- ------------------------- -------------------------------- ------------------ ------------------------- ------------------- -------------------
  Abatacept                     49                                                  11.2                  16--17                       12.3                      17--18                           12.4               17--18                    12.0                17.2

  Adalimumab                    46                                                  11.2                  16--17                       12.7                      17--18                           12.8               17--18                    12.2                17.2

  Allopurinol                   53                                                  10.8                  15--16                       10.5                      15--16                           11.5               16--17                    10.9                15.8

  Apremilast                    56                                                  10.6                  15--16                       11.3                      16--17                           11.7               16--17                    11.2                16.2

  Azathioprine                  50                                                  10.7                  15--16                       11.6                      16--17                           12.2               17--18                    11.5                16.5

  Bisphosphonates intravenous   49                                                  11.1                  16--17                       12.1                      17--18                           12.2               17--18                    11.8                17.2

  Bisphosphonates oral          49                                                  11.2                  16--17                       12.2                      17--18                           12.3               17--18                    11.9                17.2

  Bosentan                      59                                                  10.4                  15--16                       11.0                      16--17                           11.5               16--17                    11.0                16.2

  Certolizumab                  46                                                  11.1                  16--17                       12.8                      17--18                           12.9               17--18                    12.3                17.2

  Colchicine                    53                                                  11.1                  16--17                       11.7                      16--17                           11.7               16--17                    11.5                16.5

  Cyclophosphamide              53                                                  10.7                  15--16                       10.8                      15--16                           11.8               16--17                    11.1                15.8

  Ciclosporin                   54                                                  10.7                  15--16                       11.8                      16--17                           12.0               17--18                    11.5                16.5

  Denosumab                     50                                                  11.0                  16--17                       11.9                      16--17                           12.1               17--18                    11.7                16.8

  Etanercept                    48                                                  11.1                  16--17                       12.7                      17--18                           12.8               17--18                    12.2                17.2

  Febuxostat                    54                                                  10.7                  15--16                       10.8                      15--16                           11.7               16--17                    11.1                15.8

  Golimumab                     48                                                  11.1                  16--17                       12.8                      17--18                           12.8               17--18                    12.2                17.2

  Hyaluronic acid               51                                                  11.1                  16--17                       11.8                      16--17                           11.9               16--17                    11.6                16.5

  Hydroxychloroquine            49                                                  10.9                  15--16                       11.6                      16--17                           11.7               16--17                    11.4                16.2

  Infliximab                    49                                                  11.1                  16--17                       12.5                      17--18                           12.6               17--18                    12.1                17.2

  Leflunomide                   54                                                  10.7                  15--16                       11.6                      16--17                           12.2               17--18                    11.5                16.5

  Methotrexate                  52                                                  10.9                  15--16                       11.4                      16--17                           12.3               17--18                    11.5                16.5

  Mycophenolate                 50                                                  11.0                  16--17                       11.6                      16--17                           12.5               17--18                    11.7                16.8

  NSAIDs                        58                                                  10.6                  15--16                       11.0                      16--17                           11.3               16--17                    11.0                16.2

  Prednisone                    51                                                  10.9                  15--16                       11.2                      16--17                           11.9               16--17                    11.3                16.2

  Rituximab                     48                                                  11.3                  16--17                       12.3                      17--18                           12.5               17--18                    12.0                17.2

  Sulfasalazine                 50                                                  10.9                  15--16                       11.4                      16--17                           11.9               16--17                    11.4                16.2

  Teriparatide                  49                                                  10.9                  15--16                       11.6                      16--17                           12.1               17--18                    11.5                16.5

  Tocilizumab                   47                                                  11.1                  16--17                       12.0                      17--18                           12.5               17--18                    11.9                17.2

  Tofacitinib                   46                                                  11.1                  16--17                       12.1                      17--18                           12.2               17--18                    11.8                17.2

  Ustekinumab                   54                                                  10.8                  15--16                       11.5                      16--17                           12.0               17--18                    11.4                16.5

  Mean                          50.8                                                10.9                                               11.8                                                       12.1                                         11.6                16.6

  SD                            0.6                                                 0.0                                                0.1                                                        0.1                                          0.1                 0.1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Flesch Scale Value: very easy (90--100), easy (80--89), fairly easy (70--79), standard (60--69), fairly difficult (50--59), difficult (30--49), very confusing (0--29).

†Mean of FORCAST, Gunning Fog and SMOG scores.

FORCAST (named after the authors FORd, CAylor, STicht); NSAIDs, non-steroidal anti-inflammatory drugs; SMOG, Simple Measure Of Gobbledygook.

###### 

Word and sentence statistics for Australian Rheumatology Association Medicine Information Sheets

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication                    No. of sentences   No. of difficult[\*](#tblfn4){ref-type="fn"} sentences   Mean sentence length\   Total no. of words   No. of complex† words
                                                                                                            (no. of words)                               
  ----------------------------- ------------------ -------------------------------------------------------- ----------------------- -------------------- -----------------------
  Abatacept                     133                8 (5%)                                                   12.1                    1612                 314 (19.5%)

  Adalimumab                    125                11 (8.8%)                                                12.6                    1576                 315 (20%)

  Allopurinol                   124                10 (8.1%)                                                12.2                    1507                 252 (16.7%)

  Apremilast                    92                 9 (9.8%)                                                 11.9                    1095                 184 (16.8%)

  Azathioprine                  118                9 (7.6%)                                                 13                      1539                 273 (17.7%)

  Bisphosphonates intravenous   95                 11 (11.6%)                                               12.6                    1199                 217 (18.1%)

  Bisphosphonates oral          112                11 (9.8%)                                                13                      1456                 277 (19%)

  Bosentan                      107                11 (10.3%)                                               11.4                    1219                 214 (17.6%)

  Certolizumab                  125                12 (9.6%)                                                13                      1624                 320 (19.7%)

  Colchicine                    123                8 (6.5%)                                                 11.6                    1426                 260 (18.2%)

  Cyclophosphamide              118                12 (10.2%)                                               12.4                    1469                 266 (18.1%)

  Ciclosporin                   102                8 (7.8%)                                                 12.1                    1235                 227 (18.4%)

  Denosumab                     110                10 (9.1%)                                                12                      1317                 243 (18.5%)

  Etanercept                    124                11 (8.9%)                                                13.1                    1621                 321 (19.8%)

  Febuxostat                    120                12 (10%)                                                 12.4                    1484                 255 (17.2%)

  Golimumab                     123                12 (9.8%)                                                12.9                    1588                 316 (19.9%)

  Hyaluronic acid               81                 4 (4.9%)                                                 11.3                    919                  181 (19.7%)

  Hydroxychloroquine            87                 9 (10.3)                                                 12                      1046                 184 (17.6%)

  Infliximab                    138                13 (9.4%)                                                13.1                    1807                 344 (19%)

  Leflunomide                   111                10 (9%)                                                  12.9                    1427                 254 (17.8%)

  Methotrexate                  156                20 (12.8%)                                               13.4                    2097                 375 (17.9%)

  Mycophenolate                 141                15 (10.6%)                                               12.1                    1712                 334 (19.5%)

  NSAIDs                        137                14 (10.2%)                                               12.8                    1750                 266 (15.2%)

  Prednisone                    128                12 (9.4%)                                                13                      1668                 292 (17.5%)

  Rituximab                     132                9 (6.8%)                                                 12.3                    1627                 318 (19.5%)

  Sulfasalazine                 124                9 (7.3%)                                                 12.1                    1497                 276 (18.4%)

  Teriparatide                  114                13 (11.4%)                                               11.5                    1310                 238 (18.2%)

  Tocilizumab                   130                12 (9.2%)                                                12.7                    1654                 311 (18.8%)

  Tofacitinib                   111                7 (6.3%)                                                 12                      1336                 249 (18.6%)

  Ustekinumab                   114                8 (7%)                                                   12.3                    1406                 259 (18.4%)

  Mean                          118.5              10.7 (9.0%)                                              12.4                    1474.1               271.2 (18.4%)

  SD                            3.0                0.5                                                      0.1                     44.6                 9.0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Difficult sentence: ≥22 words.

†Complex word: ≥3 syllables.

NSAIDs, non-steroidal anti-inflammatory drugs.

As the validity of the above readability assessment measures has been questioned due to over-reliance on sentence and word length,[@R47] we proceeded to assess patient literal comprehension of the ARA MIS.

Assessment of comprehension {#s3b}
---------------------------

A total of 261 patients were contacted, with 95 study participants ([figure 1](#F1){ref-type="fig"}). Mean (±SD) age of study participants was 60±13.2 years, with 71/95 (75%) women and 24/95 (25%) men ([table 3](#T3){ref-type="table"}). Nineteen of the 95 (20%) patients had a university degree ([table 3](#T3){ref-type="table"}). Only 9/21 (43%) and 13/24 (54.2%) patients correctly answered all five questions for adalimumab and ABA, respectively ([table 3](#T3){ref-type="table"}). Only 7/11 (63.6%) of patients correctly answered all five simple questions assessing literal comprehension of the MTX MIS ([table 3](#T3){ref-type="table"}). Questions assessing comprehension of the prednisone MIS were correctly answered by most participants (10/11; 90.9%). Of concern, only 21.4% (6/28) of patients correctly answered all questions assessing comprehension of the NSAID MIS. Responses to the five NSAID questions are shown in [figure 2](#F2){ref-type="fig"}.

![Answers to NSAID questions.](bmjopen-2018-024582f02){#F2}

###### 

Assessment of patient literal comprehension (n=95 patients)

  ---------------------------------------- --------------
  Age (years, mean ±SD)                    60.0±13.2
  Sex (F/M)                                71/24
  Highest level of education               no. (%)
   ≤Year 10                                39 (41)
   Year 10--12                             15 (16)
   Subdegree, eg, TAFE, apprenticeship     22 (23)
   University degree                       19 (20)
  Median total score (max=5)               4
  No. with all correct answers (ie, 5/5)   no. (%)
   Adalimumab                              9/21 (43)
   MTX                                     7/11 (63.6)
   NSAIDs                                  6/28 (21.4)
   Prednisone                              10/11 (90.9)
   Abatacept                               13/24 (54.2)
  ---------------------------------------- --------------

MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; TAFE, technical and further education.

Highest level of education achieved (r=0.33, p=0.001) and age (r=−0.3, p=0.0002) correlated moderately strongly with a higher comprehension score.

Comparison of readability scores for Australian, UK and Canadian MIS {#s3c}
--------------------------------------------------------------------

Given our findings, we sought to determine using Readability Studio what the readability scores were for MIS used in other countries. The mean (±SD) grade level for 10 of the commonly used UK MIS was 11.8±0.1 with a reader age of 16.9±0.1 years ([table 4](#T4){ref-type="table"}). The mean Flesch Reading Ease score was 48.5±1.5 classified as 'difficult'. Readability of the Canadian MIS was easier with a mean (±SD) grade level of 9.7±0.1 and mean (±SD) reader age of 14.8±0.1 years ([table 5](#T5){ref-type="table"}). The mean (±SD) Flesch Reading Ease score for the Canadian MIS was 66.1±1.0 classified as 'standard'.[@R33]

###### 

Readability scores for Arthritis Research United Kingdom Medicine Information Sheets

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication           Flesch Reading Ease[\*](#tblfn8){ref-type="fn"}\   FORCAST grade level   FORCAST reader age   Gunning Fog grade level   Gunning Fog reader age\   SMOG grade level   SMOG reader age\   Mean grade level †   Mean reader age†\
                       (0--100)                                                                                                                (years)                                      (years)                                 (years)
  -------------------- -------------------------------------------------- --------------------- -------------------- ------------------------- ------------------------- ------------------ ------------------ -------------------- -------------------
  Abatacept            46                                                 10.9                  15--16               13.1                      18--19                    13.2               18--19             12.4                 17.5

  Adalimumab           47                                                 11.1                  16--17               12.1                      17--18                    12.5               17--18             11.9                 17.2

  Bisphosphonates      53                                                 11.1                  16--17               11.9                      16--17                    12.3               17--18             11.8                 16.8

  Denosumab            42                                                 11.7                  16--17               12                        17--18                    12.6               17--18             12.1                 17.2

  Etanercept           49                                                 11                    16--17               11.9                      16--17                    12.4               17--18             11.8                 16.8

  Hydroxychloroquine   41                                                 11.2                  16--17               12.5                      17--18                    12.5               17--18             12.1                 17.2

  Leflunomide          53                                                 10.8                  15--16               11.9                      16--17                    12.2               17--18             11.6                 16.5

  Methotrexate         51                                                 10.8                  15--16               12.1                      17--18                    12.4               17--18             11.8                 16.8

  Prednisolone         55                                                 11.1                  16--17               11.3                      16--17                    11.6               16--17             11.3                 16.5

  Sulfasalazine        48                                                 10.8                  15--16               11.9                      16--17                    12.2               17--18             11.6                 16.5

  Mean                 48.5                                               11.1                                       12.1                                                12.4                                  11.8                 16.9

  SD                   1.5                                                0.1                                        0.1                                                 0.1                                   0.1                  0.1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Flesch Scale Value: very easy (90--100), easy (80--89), fairly easy (70--79), standard (60--69), fairly difficult (50--59), difficult (30-- 49), very confusing (0--29).

†Mean of FORCAST, Gunning Fog and SMOG scores.

FORCAST (named after the authors FORd, CAylor, STicht); SMOG, Simple Measure Of Gobbledygook.

###### 

Readability scores for Canadian Medicine Information Sheets

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication           Flesch Reading Ease [\*](#tblfn11){ref-type="fn"}\   FORCAST grade level   FORCAST reader age\   Gunning Fog grade level   Gunning Fog reader age\   SMOG grade level   SMOG reader age\   Mean grade level†   Mean reader age†\
                       (0--100)                                                                   (years)                                         (years)                                      (years)                                (years)
  -------------------- ---------------------------------------------------- --------------------- --------------------- ------------------------- ------------------------- ------------------ ------------------ ------------------- -------------------
  Abatacept            65                                                   10                    15--16                8.5                       13--14                    10.3               15--16             9.6                 14.8

  Adalimumab           61                                                   10.1                  15--16                9.8                       14--15                    10.2               15--16             10                  15.2

  Bisphosphonates      63                                                   10.2                  15--16                9.5                       14--15                    10                 15--16             9.9                 15.2

  Denosumab            66                                                   9.6                   14--15                9.6                       14--15                    10                 15--16             9.7                 14.8

  Etanercept           64                                                   10.1                  15--16                9.9                       14--15                    10.3               15--16             10.1                15.2

  Hydroxychloroquine   72                                                   8.8                   13--14                8.4                       13--14                    9.5                14--15             8.9                 13.8

  Leflunomide          67                                                   9.9                   14--15                9.4                       14--15                    9.9                14--15             9.7                 14.5

  Methotrexate         66                                                   9.8                   14--15                9.5                       14--15                    10.1               15--16             9.8                 14.8

  Prednisolone         69                                                   10.2                  15--16                9.8                       14--15                    10.1               15--16             10                  15.2

  Sulfasalazine        68                                                   9.3                   14--15                9.1                       14--15                    9.7                14--15             9.4                 14.5

  Mean                 66.1                                                 9.8                                         9.4                                                 10.0                                  9.7                 14.8

  SD                   1.0                                                  0.1                                         0.2                                                 0.1                                   0.1                 0.1
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Flesch Scale Value: very easy (90--100), easy (80--89), fairly easy (70--79), standard (60--69), fairly difficult (50--59), difficult (30--49), very confusing (0--29).

†Mean of FORCAST, Gunning Fog and SMOG scores.

FORCAST (named after the authors FORd, CAylor, STicht); SMOG, Simple Measure Of Gobbledygook.

There was no significant difference in mean grade levels between the Australian and UK MIS (p=0.10). However, the mean grade level of the Canadian MIS (9.7±0.1) was less than that of the corresponding Australian MIS (11.7±0.1, p\<0.0001).

The Australian MIS were the longest (mean ±SD, number of words=1474.1±44.6) ([table 2](#T2){ref-type="table"}) compared with the UK (mean ±SD, number of words=922.4±109.6) ([table 6A](#T6){ref-type="table"}) and Canadian MIS (mean ±SD, number of words=297.7 ± 19.2) ([table 6B](#T6){ref-type="table"}). The Australian MIS also had the highest percentage of complex words (three or more syllables, 18%), compared with the UK (16%) and Canadian (14%) MIS.

###### 

Word and sentence statistics for (A) UK and (B) Canadian Medicine Information Sheets

  Drug                  No. of sentences   No. of difficult\* sentences   Mean sentence length (no. of words)   No. of words   No. of complex† words
  --------------------- ------------------ ------------------------------ ------------------------------------- -------------- -----------------------
  \(A\) UK                                                                                                                     
   Abatacept            66                 18 (27%)                       17.1                                  1130           206 (18%)
   Adalimumab           71                 10 (14%)                       15.3                                  1086           191 (18%)
   Bisphosphonates      36                 10 (28%)                       15.7                                  566            92 (16%)
   Denosumab            8                  2 (25%)                        14.4                                  115            22 (19%)
   Etanercept           81                 16 (20%)                       15.8                                  1282           214 (17%)
   Hydroxychloroquine   60                 13 (22%)                       15.3                                  916            159 (17%)
   Leflunomide          63                 12 (19%)                       16.1                                  1016           157 (15%)
   Methotrexate         75                 13 (17%)                       16.2                                  1212           193 (16%)
   Prednisolone         60                 15 (25%)                       17                                    1020           131 (13%)
   Sulfasalazine        53                 12 (23%)                       16.6                                  881            132 (15%)
   Mean                 57.3               12.1 (21%)                     15.95                                 922.4          149.7 (16%)
   SD                   6.7                1.4                            0.3                                   109.6          18.7
  \(B\) Canadian                                                                                                               
   Abatacept            25                 0                              11.1                                  278            38 (14%)
   Adalimumab           31                 0                              11                                    341            47 (14%)
   Bisphosphonates      30                 0                              10                                    301            41 (14%)
   Denosumab            24                 0                              10.3                                  246            34 (14%)
   Etanercept           31                 0                              10.9                                  339            48 (14%)
   Hydroxychloroquine   21                 0                              9.3                                   195            23 (12%)
   Leflunomide          34                 0                              10                                    339            46 (14%)
   Methotrexate         32                 0                              11.2                                  357            47 (13%)
   Prednisolone         36                 0                              10.1                                  363            53 (15%)
   Sulfasalazine        21                 0                              10.4                                  218            27 (12%)
   Mean                 28.5               0                              10.43                                 297.7          40.4 (14%)
   SD                   1.7                0.0                            0.2                                   19.2           3.1

\*Difficult sentence: ≥22 words.

†Complex word: ≥3 syllables.

Discussion {#s4}
==========

We showed that the readability of commonly used rheumatology MIS given to patients in Australia, the UK and Canada exceeded eighth grade level---the recommended level for a low-literacy population.[@R11] The Canadian MIS assessed were easier to read, although remained slightly above eighth grade level. We found that in a population of patients attending a regional private rheumatology practice where only 20% of participants possessed a university degree, patient comprehension of the Australian MIS was poor, with up to 79% of patients failing to correctly answer all five simple questions assessing literal comprehension of commonly prescribed rheumatology medications. As expected, a higher level of education achieved was associated with better comprehension (r=0.33, p=0.001). This, along with high readability scores, suggested that current ARA MIS may be too difficult for many patients to understand. While comprehension of the Canadian MIS was not performed, this would provide useful information about the effectiveness of these easier-to-read materials.

The Canadian MIS were simpler, more 'readable' and included pictures. Many studies have shown that incorporating pictograms into patient information material improves patient comprehension.[@R49] One study of 60 patients showed that pictograms improved comprehension of patient information sheets from 40% to 93%.[@R50] Another strategy to improve MIS readability is to shorten the document. However, a shorter, simpler MIS may remove important information and be inadequate for patients with high literacy. Yet, studies have shown both low and high literacy groups recalled information best when the text was easy.[@R55] These findings suggest that written materials designed for patients with low health literacy may also be useful for a general audience.

It is important to consider the primary purpose of providing written health-related information to a patient. Although the provision of information as part of patient education to facilitate informed patient treatment decisions is important, worry over potential medicolegal exposure from a treatment-related adverse event continues to drive complexity of written materials.[@R56]

Potential limitations of this study include the type of population studied and the measures used to assess readability. All study participants were from Coffs Harbour, a large regional community on the east coast of Australia. Although one may expect literacy levels to be lower in a rural setting, previous work from our centre showed no difference in health literacy between our patients compared with an urban rheumatology private practice in a capital city.[@R23]

There has been criticism of readability formulae such as the Flesch Reading Ease formula, SMOG scale and the Gunning Fog scale.[@R48] Readability formulae are usually based solely on word length or syllable number. They may therefore fail to adjust for patient familiarity with vocabulary associated with their illness, therefore overestimating the difficulty of written information when read by patients familiar with their disease.[@R57] By necessity, health-related written material uses text characterised by polysyllabic technical jargon, which elevates readability formulae scores.[@R60] For example, exchanging 'adalimumab' for 'Humira' in the Australian MIS increases the Flesch Reading ease score from 46 to 50 and reduces the Gunning Fog score from 12.7 to 12.5 (the SMOG remains unchanged at 12.8). Readability formulae fail to account for the stylistic properties of text as well as grammatical errors, which influences the readability of written text. Textual coherence, that is, the relationship and connection between sentences within a document and the relationship between the reader and practitioner are also unaccounted for. Finally, readability formulae do not usually consider visual and design factors which may influence MIS readability or patient comprehension.[@R61] While the Flesch Reading Ease formula tends to over-estimate readability of health-related material due to its lower level of expected comprehension criteria,[@R58] the SMOG formula is appropriate for assessing health-related written information as it has been validated against 100% comprehension.[@R58] One approach to addressing these limitations is the use of a more holistic linguistic framework for assessing written patient information which incorporates structure, factual content and visual aspects of the material as well as the relationship between writer and reader.[@R48] This method has been validated using RA medication leaflets in an Australian cohort of patients with RA.[@R63] However, the education level of patients in that study exceeded that seen in our cohort, with 17/27 (63%) having completed tertiary studies compared with 19/95 (20%) in ours.

In view of the potential limitations of readability formulae, we were careful to assess patient literal comprehension of various ARA MIS. As suggested by the relatively low readability scores of the ARA MIS, patient literal comprehension of a selection of the ARA MIS was poor. Due to the simplicity of the five questions posed to the patients, we hoped a satisfactory score would be correct answers to all five questions. However, this only occurred in 21% of patients for NSAIDs and 40%--60% of patients for the MTX, ADA and ABA MIS.

Despite the confines and limitations of readability formulae, we believe they remain an important guide when developing written patient information or revising original drafts. This has been validated by several studies that used these formulae to simplify existing written patient information---resulting in enhanced patient comprehension.[@R64] We hope the results of this study will encourage clinicians from rheumatology and all other specialities to consider the health literacy of their patients and readability of the written information they provide, particularly given the potential of technology to improve patient education.

Conclusion {#s5}
==========

Medication information sheets currently used by many rheumatologists in Australia, the UK and Canada exceed eighth grade level---the recommended level for a low-literacy population. This may explain why patient comprehension of the information contained in these materials is limited. Comprehension may be improved using simpler, shorter words and sentences with greater use of pictures and infographics. This may lead to greater patient medication adherence, understanding of their condition and reduced medication-related errors. It is hoped our findings will encourage all healthcare professionals to consider the appropriateness of written healthcare material provided to patients. The health literacy of patients should always be considered when communicating a management plan.
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